MedPath

Evaluation of Pain Level Reduction After Low-dose Radiation in Symptomatic Facet Joint Arthritis

Not Applicable
Terminated
Conditions
Osteoarthritis, Spine
Lower Back Pain Chronic
Facet Joint Arthrosis
Interventions
Drug: Intra-articular steroid injections
Radiation: Low-dose radiation therapy
Registration Number
NCT05852808
Lead Sponsor
Silvia Gomez Ordonez
Brief Summary

The goal of this clinical trial is to compare low-dose radiation therapy (LDRT) with intra-articular steroid injections in participants suffering from chronic lower back pain as cause of facet joint arthritis (FJA).

The main question\[s\] it aims to answer are:

* Is LDRT non-inferior to intra-articular steroid injections in terms of pain reduction

* Is there a difference in long-term pain reduction between LDRT and intra-articular steroid injections Participants will be randomly assigned to one of the two treatment groups.

Detailed Description

However, there has been no published study providing scientific evidence by prospective randomized data on the effect of LDRT in patient suffering from facet osteoarthritis. LDRT seems a viable treatment method with anti-inflammatory potential and possible long-lasting benefit in pain resolution for patients with facet joint arthritis (FJA), which can prevent from an ultimate surgical treatment.

The rationale of this trial is to generate scientific evidence that LDRT is an alternative non-invasive treatment option for FJA, whose primary outcome "pain reduction" is equivalent to the most common treatment intra-articular steroid injections.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
5
Inclusion Criteria
  • Patients with degenerative symptomatic facet joint osteoarthritis confirmed by MRI (lumbar spine) and standing X-ray
  • Patients who underwent treatment for facet joint syndrome at the Dept. of Orthopaedic Surgery and Traumatology of KSA (Kantonsspital Aarau) or Dept. of Rheumatology of KSA or Dept. of Neurosurgery of KSA, onset of symptoms and treatment with pain medication and physiotherapy
  • The informed consent form for participation in the study was signed
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥ 45 years
  • Karnofsky Performance Status (KPS) ≥ 80 %
  • Ability to take steroids and bridge or pause NOAC (New oral anticoagulants) / Marcoumar
  • Show a positive Tracer-Uptake in the SPECT-CT in max. 4 facet joints of the lumbar spine (regardless of radiologic changes in MRI or CT)
  • Immediate ≥ 70% pain reduction after 1 positive diagnostic infiltration of the suspected facet joint(s)
  • Negative middle-/long-term effect (4-12 weeks after first steroid injection, defined as "NRS 5-10 at 4-12 weeks")
Exclusion Criteria
  • Any previous infiltration therapy in the suspected spine region (+/- 3 segments) within the last 3 years
  • Any previous radiotherapy, radiofrequency ablation, other pain modulating interventions (e.g. thermos/-cryoablation or spinal cord stimulators) or surgery in the suspected spine region (+/- 3 segments)
  • Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except: nonmelanoma skin cancer, cervix carcinoma in situ, prostatic intraepithelial neoplasia) Contraindications to radiotherapy (for example connective tissue disorders such as scleroderma)
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Pregnancy, desire to have own children or lactation during study participation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intra-articular steroid injectionsIntra-articular steroid injectionsThe intra-articular steroid injections are the most common standard of care to treat the lower back pain resulting from FJA.
Low-dose radiation therapyLow-dose radiation therapyLDRT is commonly used as treatment for benign degenerative inflammatory disorders
Primary Outcome Measures
NameTimeMethod
Change in pain level, measured on a numeric rating scale (NRS)Baseline and 3 month after randomization

Difference in pain score on a numeric rating scale (NRS) with values from 0 to 10 (0 = no pain, 10 = highest imaginable pain)

Secondary Outcome Measures
NameTimeMethod
Percentage of patients with NRS<4 (equals responders) after six monthsAt six months

Efficacy of LDRT measured by percentage of patients with NRS\<4

Number of reported (serious) adverse events ((S)AE)Up to 12 months

Toxicity of LDRT measured by number and description of reported (S)AE (serious adverse events)

Change in pain level, measured on a numeric rating scale (NRS)Baseline, at 6 and 12 months after randomization

Difference in pain score on a numeric rating scale (NRS) with values from 0 to 10 (0 = no pain, 10 = highest imaginable pain)

Percentage of patients with NRS<4 (equals responders) after first treatment sessionUp to 3.5 weeks

Efficacy of LDRT measured by percentage of patients with NRS\<4 (equals responders) after first treatment session.

Change in quality of life measured by the Short Form Health (SF)-36 questionnaireBaseline, at 3, 6 and 12 months after randomization

The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The eight sections are:

vitality physical functioning bodily pain general health perceptions physical role functioning emotional role functioning social role functioning mental health or emotional wellbeing

Trial Locations

Locations (1)

Kantonsspital Aarau

🇨🇭

Aarau, Switzerland

© Copyright 2025. All Rights Reserved by MedPath